Phase 2 N=41 Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Recurrent Glioblastoma
Primary: Progression Free Survival (PFS) — 34.5 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=32 A New Clinical Use of Ferumoxytol Nanoparticles: An Antibiofilm Treatment
Apical Periodontitis · Pulp Disease, Dental
Primary: The Primary Outcome Parameter Will be the Difference in Bacterial Reduction Between the Experimental and Control Disinfection Groups Group (Ferumoxytol) and Comparison…
Phase 3 N=66 Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies
Lung Transplant; Complications, Mechanical · Lung Transplant; Complications · Bleeding
Primary: Intra-procedural Hemorrhage Grading by the Performing Bronchoscopist — 4; 13; 11; 24 Procedures
Phase 1 N=49 Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship
Stage 0a Bladder Cancer AJCC v8 · Stage 0is Bladder Cancer AJCC v8 · Stage I Bladder Cancer AJCC v8
Primary: Urinary Isothiocyanates Levels — 10.4; 4.3 mM — p=0.28
Phase 2 N=313 Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)
Leprosy
Primary: Mean Difference in QTc Interval Between the Two Arms 24 Hours After Treatment Administration — 396.81; 397; 404.61; 394.06 msec
N/A N=139 Virtual Human Delivered Nutrition Module for Colorectal Cancer Prevention
Colorectal Cancer
Primary: Risk Perceptions for Colorectal Cancer — 3.3; 3.6; 3.5 score on a scale
Phase 3 N=161 HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose
Amyotrophic Lateral Sclerosis
Primary: Disease Progression as Assessed by the ALSFRS-R Slope — -0.91; -1.06 points per month
Phase 4 N=72 Empagliflozin and Hepatic Glucose Metabolism
Hepatic Glucose Metabolism
Primary: Effect of Empagliflozin on Autonomic Nervous System — 480; 621; 355; 635 ng/min
Phase 2 N=28 Effects of Tolcapone on Frontotemporal Dementia
Frontotemporal Lobar Degeneration
Primary: Reaction Time on the N-back Cognitive Test (0-back Condition) — 7935; 8322 milliseconds
Phase 3 N=85 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Number of Participants With Any Treatment-emergent Serious Adverse Events (SAEs) and Adverse Events (AEs), Regardless of Causality — 76; 20 Participants
N/A N=1,901 Messages About Reduced Nicotine in Combusted Tobacco Products
Health Communication · Smoking · Smoking, Tobacco
Primary: Perceived Health Risk of VLNCs (Absolute) — 4.09; 3.81; 4.03; 3.87 score on a scale
N/A N=8 A Mobile Tai Chi Platform for Fall Prevention and Cognition in Older Adults
Aging · Fall
Primary: Protocol Adherence — 78.6 percentage of sessions completed
Phase 2 N=52 AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL
Relapsed/Refractory Peripheral T-cell Lymphoma · Relapsed/Refractory Classical Hodgkins Lymphoma
Primary: Objective Response Rate (ORR) — 22.6; 0; 21.1 Percentage of participants
N/A N=260 Drug Reduction in Older Patients: The DROP Trial
Geriatric Assessment · Frail Elderly · Skilled Nursing Facilities
Primary: Total Number of Medications — 15; 13; 15.5; 14 Medications — p=0.006
Phase 2 N=46 A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment
Diabetic Retinopathy
Primary: Single Rising Dose Part - Number of Subjects With Ocular Dose Limiting Events (DLEs) From Drug Administration Until Day 8 (7 Days After Treatment) — 0; 0; 0 Participants